Sapc-dops nanovesicles for treating glioblastoma multiforme
Ended Cooperative Agreement Awarded Last action
- Award ID
- R44CA136017
- Recipient
-
Bexion Pharmaceuticals, Inc. UEI HJPDQTK95NS8
- Awarding agency
-
National Institutes of Health
Department of Health and Human Services
- Obligated
- $4,368,595
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Funding agency
- Department of Health and Human Services
- Place of performance
- Park Hills, KY 41011, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $948,501 | |
| Amendment | $948,501 | |
| Amendment | $960,270 | |
| Amendment | $840,956 | |
| Original award | $670,367 |
Quick answers
Who received award R44CA136017?
R44CA136017 was awarded to Bexion Pharmaceuticals, Inc. by National Institutes of Health (Department of Health and Human Services) on August 1, 2008.
How much is award R44CA136017 worth?
$4,368,595 has been obligated on R44CA136017.
Which agency awarded R44CA136017?
National Institutes of Health (Department of Health and Human Services) awarded R44CA136017, with funding from Department of Health and Human Services.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award